Literature DB >> 6294676

Brain cyclic AMP and memory in mice.

C T Randt, M E Judge, K A Bonnet, D Quartermain.   

Abstract

A phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (Rolipram, 10 mg/kg IP) administered immediately, but not 3 hr post-training, reversed an amnesia for an inhibitory avoidance response induced by the protein synthesis inhibitor anisomycin. Immediate post-training administration of Rolipram also enhanced retention for a weakly learned avoidance response. Unshocked animals did not show increased test latencies thus ruling out conditioned aversion as an explanation for the enhanced avoidance. Mice treated with Rolipram (10 mg/kg after training showed elevated cyclic AMP but not cyclic GMP in frontal cortex, thalamus, and hypothalamus. These results support the suggestion that cyclic AMP may play a role in memory processes.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6294676     DOI: 10.1016/0091-3057(82)90344-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  18 in total

Review 1.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 2.  Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I.

Authors:  M Sarter; J Hagan; P Dudchenko
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Epac signaling is required for hippocampus-dependent memory retrieval.

Authors:  Ming Ouyang; Lei Zhang; J Julius Zhu; Frank Schwede; Steven A Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-07       Impact factor: 11.205

Review 4.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

5.  Compartmentalized PDE4A5 Signaling Impairs Hippocampal Synaptic Plasticity and Long-Term Memory.

Authors:  Robbert Havekes; Alan J Park; Rosa E Tolentino; Vibeke M Bruinenberg; Jennifer C Tudor; Yool Lee; Rolf T Hansen; Leonardo A Guercio; Edward Linton; Susana R Neves-Zaph; Peter Meerlo; George S Baillie; Miles D Houslay; Ted Abel
Journal:  J Neurosci       Date:  2016-08-24       Impact factor: 6.167

6.  Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives.

Authors:  D Bobon; M Breulet; M A Gerard-Vandenhove; F Guiot-Goffioul; G Plomteux; M Sastre-y-Hernández; M Schratzer; B Troisfontaines; R von Frenckell; H Wachtel
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

7.  Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.

Authors:  Edward W Vogel; Fatima N Morales; David F Meaney; Cameron R Bass; Barclay Morrison
Journal:  Exp Neurol       Date:  2017-03-31       Impact factor: 5.330

8.  Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory.

Authors:  M Barad; R Bourtchouladze; D G Winder; H Golan; E Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  TVX 2706--a new phosphodiesterase inhibitor with antiinflammatory action. Biochemical characterization.

Authors:  T Glaser; J Traber
Journal:  Agents Actions       Date:  1984-10

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.